A Randomized, Double-Blind, Sponsor Unblinded, Placebo- And Positive- Controlled Study To Evaluate The Effects Of Single Oral Administrations Of PF-04995274, Alone Or In Combination With Donepezil, On Scopolamine-Induced Deficits In Psychomotor And Cognitive Function In Healthy Adults.

Trial Profile

A Randomized, Double-Blind, Sponsor Unblinded, Placebo- And Positive- Controlled Study To Evaluate The Effects Of Single Oral Administrations Of PF-04995274, Alone Or In Combination With Donepezil, On Scopolamine-Induced Deficits In Psychomotor And Cognitive Function In Healthy Adults.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2012

At a glance

  • Drugs PF 4995274 (Primary) ; Donepezil
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2011 Planned end date changed from 1 Oct 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 12 Oct 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top